Crossref
Milestone cancer vaccine success leaves hard questions unanswered
Science · 29.10.2026 · 394 (6823) · 478-479
DOI: 10.1126/science.aen6356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 29.10.2026. Verfasst von Jocelyn Kaiser. Hauptthemen laut MEDLINE: Cancer Vaccines, Melanoma, mRNA Vaccines, Neoplasm Recurrence, Local.
Abstract (Originalsprache)
Messenger RNA vaccine from Merck and Moderna slashes risk of melanoma’s return, but why remains unclear
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Cancer VaccinesMelanomamRNA VaccinesNeoplasm Recurrence, LocalHumansClinical Trials, Phase III as Topic
Substanzen
Cancer VaccinesmRNA Vaccines
Zitieren
APA
Kaiser, J. (2026). Milestone cancer vaccine success leaves hard questions unanswered. Science, 394(6823), 478-479. https://doi.org/10.1126/science.aen6356
Vancouver
Kaiser J. Milestone cancer vaccine success leaves hard questions unanswered. Science. 2026;394(6823):478-479. doi:10.1126/science.aen6356
BibTeX
@article{Kaiser2026,
author = {Kaiser, Jocelyn},
title = {Milestone cancer vaccine success leaves hard questions unanswered},
journal = {Science},
year = {2026},
volume = {394},
number = {6823},
pages = {478--479},
doi = {10.1126/science.aen6356}
}
EUVIMED